+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Late Stage Chronic Kidney Disease Therapeutics Market - Global Forecast 2026-2032- Product Image
Late Stage Chronic Kidney Disease Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Late Stage Chronic Kidney Disease Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6120261
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Late Stage Chronic Kidney Disease Therapeutics Market is projected to reach USD 14.16 Billion in 2026. It is expected to continue growing at a CAGR of 9.88%, reaching USD 25.20 Billion by 2032.

Late-Stage Chronic Kidney Disease Therapeutics: Executive Summary

Late-stage chronic kidney disease (CKD) therapeutics address patients at elevated risk of kidney failure, cardiovascular complications, hospitalization, and premature mortality. Clinical management commonly combines disease-modifying treatment, blood-pressure control, glycemic management where relevant, anemia care, mineral and bone disorder management, dietary intervention, and preparation for kidney replacement therapy. Treatment selection depends on estimated glomerular filtration rate, albuminuria, comorbidities, contraindications, tolerability, and access to specialist care.

The therapeutic landscape is shifting from complication management alone toward earlier, integrated risk reduction. Evidence-based care increasingly emphasizes slowing loss of kidney function, reducing cardiovascular risk, coordinating multidisciplinary services, and preparing patients for dialysis or transplantation when progression remains likely.

Integrated Care and Disease Modification Are Reshaping Late-Stage CKD Management

A major shift is the movement toward layered treatment pathways that address multiple drivers of progression rather than relying on a single intervention. Renin-angiotensin system blockade remains important for appropriate patients with albuminuria, while sodium-glucose cotransporter-2 inhibition has expanded the role of kidney-protective therapy across relevant diabetic and non-diabetic populations, subject to kidney function and safety criteria. Nonsteroidal mineralocorticoid receptor antagonism has also become relevant for selected patients with diabetic kidney disease.

Care delivery is becoming more multidisciplinary and protocolized. Nephrologists, primary-care clinicians, endocrinologists, cardiologists, pharmacists, dietitians, nurses, and transplant teams increasingly coordinate medication review, laboratory monitoring, cardiovascular prevention, anemia assessment, potassium management, and treatment planning. At the same time, regulatory eligibility, reimbursement rules, formulary restrictions, and the ability to monitor adverse events continue to influence real-world adoption.

Artificial Intelligence Is Strengthening Risk Stratification, Monitoring, and Care Coordination

Artificial intelligence can improve late-stage CKD management by identifying patients at high risk of rapid progression, acute kidney injury, hospitalization, or transition to kidney replacement therapy. Models can combine laboratory trends, medication histories, comorbidities, imaging, claims data, and clinical notes to support earlier referral and more individualized follow-up. Natural-language processing may also help extract albuminuria, dialysis planning, and contraindication information from fragmented records.

The benefits are conditional on data quality and clinical validation. CKD data are often incomplete, generated across disconnected systems, and affected by differences in laboratory practice and coding. Models therefore require external validation, transparent performance reporting, monitoring for bias across demographic and geographic groups, and clear clinician oversight. AI should support-not replace-shared decision-making, medication safety checks, and patient communication.

Regional Insights: Access, Diagnosis, and Specialist Capacity Differ Materially

North America generally combines strong specialist capacity, advanced laboratory infrastructure, and broad access to innovative therapies, but affordability, insurance design, and inequities in primary-care and nephrology access remain important constraints. Europe benefits from established clinical guidelines and coordinated health systems, while country-level reimbursement, procurement, and referral practices vary. Asia-Pacific contains highly developed systems alongside settings where late diagnosis, workforce shortages, and uneven dialysis and transplant access remain significant challenges.

Latin America continues to face differences in public and private coverage, urban-rural access, and availability of kidney replacement services. The Middle East has invested in specialist infrastructure and chronic-disease care, but diabetes burden, workforce distribution, and cross-border variation affect outcomes. Africa faces especially substantial gaps in screening, laboratory capacity, nephrology coverage, medicines, and dialysis availability, making prevention, task-sharing, and scalable care pathways central priorities.

Group Insights: Economic and Security Blocs Shape Implementation Conditions

ASEAN markets require strategies that accommodate wide differences in health-system maturity, urbanization, reimbursement, and specialist availability. BRICS members collectively illustrate the importance of domestic manufacturing, public procurement, affordability, and geographically distributed care, while national policies remain decisive. The European Union benefits from shared scientific and regulatory structures, yet health technology assessment, pricing, and reimbursement are implemented nationally.

G7 countries typically have strong research and clinical infrastructures, but aging populations, comorbidity, workforce pressure, and unequal access continue to influence outcomes. GCC countries have significant capacity for specialized care and digital health investment, while prevention of diabetes and hypertension and integration across public and private providers remain priorities. NATO members span diverse health systems; resilience planning, supply continuity, and interoperable clinical data are relevant to maintaining chronic-care delivery during disruptions.

Country Insights: National Disease Burdens and Health-System Structures Drive Variation

Australia combines strong clinical guidance with substantial rural and remote access challenges. Brazil and Mexico must address regional inequities and coordination between public and private care. Canada faces geographic dispersion and variable specialist access. China and India are balancing large patient populations, rapid health-system development, and differences between metropolitan and rural services. Japan, South Korea, France, Germany, Italy, Spain, and the United Kingdom have mature clinical infrastructures but must manage aging, multimorbidity, workforce demands, and differing reimbursement or referral arrangements.

The United States has extensive specialist and research capacity, alongside pronounced disparities linked to insurance, income, race, and geography. Russia faces challenges related to regional service distribution, access continuity, and health-system resilience. Across these countries, priorities include systematic albuminuria testing, timely nephrology referral, medication reconciliation, potassium and anemia monitoring, and structured preparation for dialysis or transplantation. Local guidelines and regulatory requirements should determine implementation details.

Action Priorities for Leaders: Improve Detection, Treatment Continuity, and Equity

Industry leaders should align therapeutic development and service design with clinically meaningful outcomes, including sustained kidney-function preservation, fewer cardiovascular events, reduced acute-care use, and patient-reported quality of life. Evidence generation should include patients with advanced disease and comorbidities who are often underrepresented in trials, while post-authorization studies should examine safety and effectiveness in routine practice.

Organizations should build interoperable pathways linking primary care, nephrology, cardiometabolic services, pharmacies, laboratories, and kidney replacement planning. Practical priorities include risk-based referral, simplified monitoring protocols, adherence support, affordability programs, local workforce training, and responsible use of validated digital tools. Access strategies should be tailored to public procurement, reimbursement, rural delivery, and culturally appropriate patient education rather than relying on a uniform international model.

Research Methodology: Evidence Synthesis Across Clinical, Policy, and System Variables

This executive summary uses a structured qualitative synthesis of established clinical guidance, peer-reviewed evidence, regulatory principles, health-system considerations, and publicly documented patterns in CKD care. The analysis focuses on late-stage disease management, disease progression, cardiovascular risk, complications, kidney replacement preparation, access, and implementation conditions across the specified regions, groups, and countries.

Interpretation prioritizes findings that are consistent across authoritative sources and distinguishes clinical evidence from health-system inference. No market estimates, market sizing, market shares, forecasts, or company-specific assessments are used. Country and regional observations are presented as contextual insights rather than substitutes for local epidemiology, reimbursement review, regulatory assessment, or clinical guidelines.

Conclusion: Coordinated, Risk-Based Care Is the Central Strategic Imperative

Late-stage CKD therapeutics are evolving toward integrated disease modification, complication prevention, and planned transitions to kidney replacement therapy. The greatest opportunity is not a single treatment category but a coordinated pathway that identifies risk earlier, preserves kidney function where possible, manages cardiovascular and metabolic comorbidity, and supports informed patient choices.

Success will depend on translating clinical advances into equitable delivery. Leaders should combine rigorous evidence generation with resilient supply and care systems, interoperable data, appropriately governed AI, specialist-workforce development, and payment models that reward continuity and outcomes. Regional and national adaptation will be essential because access, disease burden, infrastructure, and regulatory conditions differ substantially.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Late Stage Chronic Kidney Disease Therapeutics Market, by Treatment Type
7.1. Introduction
7.2. Dialysis
7.3. Pharmacotherapy
7.3.1. Antihypertensives
7.3.2. Erythropoiesis-Stimulating Agents
7.3.3. Phosphate Binders
7.3.4. Vitamin D Analogs
7.4. Transplantation
8. Late Stage Chronic Kidney Disease Therapeutics Market, by Disease Stage
8.1. Introduction
8.2. Stage 3
8.3. Stage 4
8.4. Stage 5
9. Late Stage Chronic Kidney Disease Therapeutics Market, by End-User
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Dialysis Centers
9.4. Home Care Settings
9.5. Hospitals
10. Late Stage Chronic Kidney Disease Therapeutics Market, by Distribution Channel
10.1. Introduction
10.2. Offline
10.3. Online
11. Late Stage Chronic Kidney Disease Therapeutics Market, by Mechanism Of Action
11.1. Introduction
11.2. Erythropoiesis Stimulation
11.3. Phosphate Binding
11.4. RAAS Inhibition
11.5. Vitamin D Receptor Activation
12. Late Stage Chronic Kidney Disease Therapeutics Market, by Formulation
12.1. Introduction
12.2. Injectable
12.3. Oral
13. Late Stage Chronic Kidney Disease Therapeutics Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Late Stage Chronic Kidney Disease Therapeutics Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Late Stage Chronic Kidney Disease Therapeutics Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Akebia Therapeutics, Inc.
17.3. Amgen Inc.
17.4. Ardelyx, Inc.
17.5. Astellas Pharma Inc.
17.6. AstraZeneca PLC
17.7. Bayer AG
17.8. Boehringer Ingelheim International GmbH
17.9. Chinook Therapeutics, Inc.
17.10. Eli Lilly and Company
17.11. FibroGen, Inc.
17.12. Gilead Sciences, Inc.
17.13. GlaxoSmithKline PLC
17.14. KBP Biosciences Co., Ltd.
17.15. Maze Therapeutics, Inc.
17.16. Novartis AG
17.17. Novo Nordisk A/S
17.18. Pfizer Inc.
17.19. ProKidney, Inc.
17.20. Travere Therapeutics, Inc.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Late Stage Chronic Kidney Disease Therapeutics Market, Years Considered for the Study
FIGURE 2. Global Late Stage Chronic Kidney Disease Therapeutics Market, Research Design
FIGURE 3. Global Late Stage Chronic Kidney Disease Therapeutics Market, Research Framework
FIGURE 4. Global Late Stage Chronic Kidney Disease Therapeutics Market, Data Triangulation
FIGURE 5. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2025 vs 2032 (%)
FIGURE 7. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2025 vs 2032 (%)
FIGURE 9. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2025 vs 2032 (%)
FIGURE 11. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2025 vs 2032 (%)
FIGURE 15. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2025 vs 2032 (%)
FIGURE 17. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Late Stage Chronic Kidney Disease Therapeutics Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Late Stage Chronic Kidney Disease Therapeutics Market Segmentation & Coverage
TABLE 2. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 3. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 4. Global Dialysis Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Dialysis Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Dialysis Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Pharmacotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Pharmacotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Pharmacotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Antihypertensives Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Antihypertensives Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Antihypertensives Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Erythropoiesis-Stimulating Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Erythropoiesis-Stimulating Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Erythropoiesis-Stimulating Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Phosphate Binders Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Phosphate Binders Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Phosphate Binders Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Vitamin D Analogs Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Vitamin D Analogs Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Vitamin D Analogs Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Transplantation Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Transplantation Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Transplantation Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 26. Global Stage 3 Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Stage 3 Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Stage 3 Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Stage 4 Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Stage 4 Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Stage 4 Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Stage 5 Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Stage 5 Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Stage 5 Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 36. Global Ambulatory Surgical Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Ambulatory Surgical Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Ambulatory Surgical Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Dialysis Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Dialysis Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Dialysis Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Home Care Settings Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Home Care Settings Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Home Care Settings Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 49. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 56. Global Erythropoiesis Stimulation Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Erythropoiesis Stimulation Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Erythropoiesis Stimulation Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Phosphate Binding Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Phosphate Binding Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Phosphate Binding Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global RAAS Inhibition Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global RAAS Inhibition Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global RAAS Inhibition Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Vitamin D Receptor Activation Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Vitamin D Receptor Activation Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Vitamin D Receptor Activation Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 69. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Late Stage Chronic Kidney Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 79. Asia-Pacific Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 80. Asia-Pacific Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 81. Asia-Pacific Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 82. Asia-Pacific Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 83. Asia-Pacific Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 84. North America Late Stage Chronic Kidney Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. North America Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 86. North America Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 87. North America Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 88. North America Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 89. North America Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 90. North America Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 91. North America Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 92. Latin America Late Stage Chronic Kidney Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Latin America Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 94. Latin America Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 95. Latin America Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 96. Latin America Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 97. Latin America Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 98. Latin America Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 99. Latin America Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 100. Europe Late Stage Chronic Kidney Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Europe Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 102. Europe Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 103. Europe Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 104. Europe Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 105. Europe Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 106. Europe Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 107. Europe Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 108. Middle East Late Stage Chronic Kidney Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Middle East Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 110. Middle East Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 111. Middle East Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 112. Middle East Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 113. Middle East Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 114. Middle East Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 115. Middle East Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 116. Africa Late Stage Chronic Kidney Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. Africa Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 118. Africa Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 119. Africa Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 120. Africa Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 121. Africa Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 122. Africa Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 123. Africa Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 124. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 125. ASEAN Late Stage Chronic Kidney Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. ASEAN Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 127. ASEAN Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 128. ASEAN Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 129. ASEAN Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 130. ASEAN Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 131. ASEAN Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 132. ASEAN Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 133. GCC Late Stage Chronic Kidney Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 134. GCC Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 135. GCC Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 136. GCC Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 137. GCC Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 138. GCC Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 139. GCC Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 140. GCC Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 141. European Union Late Stage Chronic Kidney Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 142. European Union Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 143. European Union Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 144. European Union Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 145. European Union Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 146. European Union Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 147. European Union Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 148. European Union Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 149. BRICS Late Stage Chronic Kidney Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 150. BRICS Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 151. BRICS Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 152. BRICS Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 153. BRICS Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 154. BRICS Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 155. BRICS Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 156. BRICS Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 157. G7 Late Stage Chronic Kidney Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 158. G7 Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 159. G7 Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 160. G7 Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 161. G7 Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 162. G7 Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 163. G7 Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 164. G7 Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 165. NATO Late Stage Chronic Kidney Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 166. NATO Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 167. NATO Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 168. NATO Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 169. NATO Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 170. NATO Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 171. NATO Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 172. NATO Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 173. Global Late Stage Chronic Kidney Disease Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 174. United States Late Stage Chronic Kidney Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 175. United States Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 176. United States Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 177. United States Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 178. United States Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 179. United States Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 180. United States Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 181. United States Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 182. Canada Late Stage Chronic Kidney Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 183. Canada Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 184. Canada Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 185. Canada Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 186. Canada Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 187. Canada Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 188. Canada Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 189. Canada Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 190. Mexico Late Stage Chronic Kidney Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 191. Mexico Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 192. Mexico Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 193. Mexico Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 194. Mexico Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 195. Mexico Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 196. Mexico Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 197. Mexico Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 198. Brazil Late Stage Chronic Kidney Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 199. Brazil Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 200. Brazil Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 201. Brazil Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 202. Brazil Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 203. Brazil Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 204. Brazil Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 205. Brazil Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 206. United Kingdom Late Stage Chronic Kidney Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 207. United Kingdom Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 208. United Kingdom Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 209. United Kingdom Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 210. United Kingdom Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 211. United Kingdom Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 212. United Kingdom Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 213. United Kingdom Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 214. Germany Late Stage Chronic Kidney Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 215. Germany Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 216. Germany Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 217. Germany Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 218. Germany Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 219. Germany Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 220. Germany Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 221. Germany Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 222. France Late Stage Chronic Kidney Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 223. France Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 224. France Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 225. France Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 226. France Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 227. France Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 228. France Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 229. France Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 230. Russia Late Stage Chronic Kidney Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 231. Russia Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 232. Russia Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 233. Russia Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 234. Russia Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 235. Russia Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 236. Russia Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 237. Russia Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 238. Italy Late Stage Chronic Kidney Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 239. Italy Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 240. Italy Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 241. Italy Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 242. Italy Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 243. Italy Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 244. Italy Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 245. Italy Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 246. Spain Late Stage Chronic Kidney Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 247. Spain Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 248. Spain Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 249. Spain Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 250. Spain Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 251. Spain Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 252. Spain Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 253. Spain Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 254. China Late Stage Chronic Kidney Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 255. China Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 256. China Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 257. China Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 258. China Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 259. China Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 260. China Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 261. China Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 262. India Late Stage Chronic Kidney Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 263. India Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 264. India Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 265. India Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 266. India Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 267. India Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 268. India Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 269. India Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 270. Japan Late Stage Chronic Kidney Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 271. Japan Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 272. Japan Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 273. Japan Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 274. Japan Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 275. Japan Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 276. Japan Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 277. Japan Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 278. Australia Late Stage Chronic Kidney Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 279. Australia Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 280. Australia Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 281. Australia Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 282. Australia Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 283. Australia Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 284. Australia Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 285. Australia Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 286. South Korea Late Stage Chronic Kidney Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 287. South Korea Late Stage Chronic Kidney Disease Therapeutics Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 288. South Korea Late Stage Chronic Kidney Disease Therapeutics Market Size, by Pharmacotherapy, 2017-2032 (USD Million)
TABLE 289. South Korea Late Stage Chronic Kidney Disease Therapeutics Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 290. South Korea Late Stage Chronic Kidney Disease Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 291. South Korea Late Stage Chronic Kidney Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 292. South Korea Late Stage Chronic Kidney Disease Therapeutics Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 293. South Korea Late Stage Chronic Kidney Disease Therapeutics Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 294. Global Late Stage Chronic Kidney Disease Therapeutics Market Sha

Companies Mentioned

  • AbbVie Inc.
  • Akebia Therapeutics, Inc.
  • Amgen Inc.
  • Ardelyx, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Chinook Therapeutics, Inc.
  • Eli Lilly and Company
  • FibroGen, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • KBP Biosciences Co., Ltd.
  • Maze Therapeutics, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • ProKidney, Inc.
  • Travere Therapeutics, Inc.

Related Topics

Related Reports

Late Stage Chronic Kidney Disease Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Late Stage Chronic Kidney Disease Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Late-Stage Chronic Kidney Disease Market - A Global and Regional Analysis: Focus on Indication, Treatment Modality, Distribution Channel, Country, 2026-2036 - Product Image

Late-Stage Chronic Kidney Disease Market - A Global and Regional Analysis: Focus on Indication, Treatment Modality, Distribution Channel, Country, 2026-2036

  • Report
  • Global
From
Chronic Kidney Disease - Competitive Landscape and Clinical Trial Analysis, 2026 - Product Image

Chronic Kidney Disease - Competitive Landscape and Clinical Trial Analysis, 2026

  • Report
  • 280 Pages
  • Global
From
Late Stage Chronic Kidney Disease Drugs Market Report 2026 - Product Image

Late Stage Chronic Kidney Disease Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Chronic Kidney Disease - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Chronic Kidney Disease - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.